US 11,814,416 B2
Polypeptide capable of passing through blood-brain barrier
Shupeng Li, Guangdong (CN); and Qiang Zhou, Guangdong (CN)
Assigned to SHENZHEN RUIJIAN BIOSCIENCE TECHNOLOGY LIMITED COMPANY, Guangdong (CN)
Appl. No. 17/277,552
Filed by SHENZHEN RUIJIAN BIOSCIENCE TECHNOLOGY LIMITED COMPANY, Guangdong (CN)
PCT Filed Dec. 27, 2018, PCT No. PCT/CN2018/124253
§ 371(c)(1), (2) Date Mar. 18, 2021,
PCT Pub. No. WO2020/056987, PCT Pub. Date Mar. 26, 2020.
Claims priority of application No. 201811086051.5 (CN), filed on Sep. 18, 2018.
Prior Publication US 2022/0112250 A1, Apr. 14, 2022
Int. Cl. C07K 14/435 (2006.01); A61K 47/65 (2017.01); A61P 29/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/43504 (2013.01) [A61K 47/65 (2017.08); A61P 29/00 (2018.01); A61K 38/00 (2013.01)] 13 Claims
 
1. A polypeptide comprising ziconotide, wherein the polypeptide is able to cross blood-brain barrier, wherein the polypeptide consists of ziconotide and a cell membrane penetrating peptide, or the polypeptide consists of ziconotide, a cell membrane penetrating peptide and a linker,
wherein C-terminal of the ziconotide is linked to N-terminal of a cell membrane penetrating peptide adjacently or via a linker, and
wherein the ziconotide has amino acids shown in SEQ ID NO.1, or the ziconotide is a variant of the amino acids shown in SEQ ID NO.1 with less than 4 amino acid deletions, mutations or insertions.